Hep88 mAb-initiated paraptosis-like PCD pathway in hepatocellular carcinoma cell line through the binding of mortalin (HSPA9) and alpha-enolase

Cancer Cell International

Sittiruk Roytrakul¹  Sarawut Jitrapakdee³  Pornpen Gamnarai⁴  Sirikul Manochantr⁴  Songchan Puthong²  Suthathip Kittisenachai¹  Panadda Rojpibulstit⁵ 

[1]Thailand National Center for Genetic Engineering and Biotechnology (BIOTEC), Thailand Science Park, Phahonyothin Road, Khlong Luang 12120, Pathum Thani, Thailand

[2]Antibody Production Research Unit, Institute of Biotechnology and Genetic Engineering, Chulalongkorn University, Pathum Wan 10330, Bangkok, Thailand

[3]Molecular Metabolism Research Group, Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand

[4]Faculty of Medicine, Thammasat University (Rangsit Campus), Khlong Luang 12121, Pathum Thani, Thailand

[5]Department of Preclinical Science, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand

关键词: Transmission electron microscopy;    Paraptosis-like program cell death;    Mortalin (HSPA9);    Monoclonal antibody;    Hepatocellular carcinoma;    Alpha-enolase;   

Others  :  1121679
DOI  :  10.1186/s12935-014-0069-9

 received in 2014-06-18, accepted in 2014-07-08,  发布年份 2014

【 摘 要 】

Background

Hepatocellular carcinoma (HCC) is the most prevalent hepatic cancer worldwide. Currently, a targeted therapy via monoclonal antibodies (mAbs) specific to tumor-associated antigen is undergoing continual development in HCC treatment.

Methods

In this regard, after establishing and consequently exploring Hep88 mAb’s tumoricidal effect on hepatocellular carcinoma cell line (HepG2 cell line), the Hep88 mAb’s specific antigens from both membrane and cytoplasmic fractions of HepG2 cell line were identified by 2-D gel electrophoresis and western blot analysis. After in-gel digestion and subsequent analysis by liquid chromatography-mass spectrometry (LC-MS), mortalin (HSPA9) and alpha-enolase were identified. The recombinant proteins specific to Hep88 mAb were cloned and expressed in E. coli BL21(DE3). Moreover, alteration of HepG2 and Chang liver cell line after being induced by Hep88 mAb for 1–3 days was investigated using a transmission electron microscope.

Results

The result demonstrated that Hep88 mAb can bind to the recombinant mortalin (HSPA9) and alpha-enolase. In addition, the gradual appearing of mitochondria vacuolization and endoplasmic reticulum dilatation were observed. Those characteristics might be explained by the paraptosis-like program cell death (PCD), which is induced by the binding of Hep88 mAb to mortalin (HSPA9). Mortalin depletion resulting from the formation of Hep88 mAb-mortalin (HSPA9) complex might initiate transcription-independence of p53-mediated apoptosis. Additionally, Hep88mAb-alpha-enolase complex might initiate HepG2 cells energy exhaustion by glycolysis pathway obstruction.

Conclusion

These fascinating results imply that Hep88 mAb might be a promising tool for the development of an effective treatment of HCC in the next decade.

【 授权许可】

   
2014 Rojpibulstit et al.; licensee Springer

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 5.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Veenook AP, Papandreou C, Furuse J, de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15(Suppl 4):5-13.
• [3]Attasara P, Buasom R: Hospital-Based Cancer Registry: NCI Thailand, in NCI Thailand. RumThai press Co, Ltd, Bangkok, Thailand; 2009.
• [4]Srivatanakul P, Sriplung H, Deerasmee S: Epidemiology of liver cancer: An Overview. Asian Pac J Cancer Prev 2004, 5:118-125.
• [5]Bundhamcharoen K, Odton P, Phulkerd S, Tangcharoensathien V: Burden of disease in Thailand: changes in health gap between 1999 and 2004. [http://www.biomedcentral.com/1471-2458/11/53] webciteBMC Public Health 2011, ᅟ:ᅟ. http://www.biomedcentral.com/1471-2458/11/53
• [6]World Cancer Report. IARC, Lyon; 2011.
• [7]Vatanasapt V, Sriamporn S, Vatanasapt P: Cancer control in Thailand. Jpn J Clin Oncol 2002, 32(Suppl):S82-S91.
• [8]Anzola M: Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 2004, 11(5):383-393.
• [9]Bruix J, Llovet JM: Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003, 39(Suppl 1):S59-S63.
• [10]Colombo M, Sangiovanni A: Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res 2003, 60(2):145-150.
• [11]Smela ME, Hamm ML, Henderson PT, Harris CM, Harris TM, Essigmann JM: The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci U S A 2002, 99(10):6655-6660.
• [12]Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M: Percutaneous ethanol injection therapy for liver tumors. Eur J Ultrasound 2001, 13(2):95-106.
• [13]Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006, 131(2):461-469.
• [14]Rhim H, Lim HK, Choi D: Current status of radiofrequency ablation of hepatocellular carcinoma. World J Gastrointest Surg 2010, 2(4):128-136.
• [15]Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
• [16]Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, Lamb J, Dai H, Ng IO, Sham PC, Poon RT: Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 2009, 9:389. BioMed Central Full Text
• [17]Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP: Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005, 92(10):1862-1868.
• [18]Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008, 26(18):2992-2998.
• [19]Jiang H, Wang H, Tan Z, Hu S, Wang H, Shi B, Yang L, Li P, Gu J, Wang H, Li Z: Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J Biol Chem 2011, 286(7):5913-5920.
• [20]Ho M: Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. BioDrugs 2011, 25(5):275-284.
• [21]Iannello A, Ahmad A: Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005, 24(4):487-499.
• [22]Clynes R: Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am 2006, 20(3):585-612.
• [23]Gelderman KA, Tomlinson S, Ross GD, Gorter A: Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004, 25(3):158-164.
• [24]Laohathai K, Bhamarapravati N: Culturing of human hepatocellular carcinoma. A simple and reproducible method. Am J Pathol 1985, 118(2):203-208.
• [25]Puthong S, Rojpibulstit P, Buakeaw A: Cytotoxic effect of Hep88 mAb: a novel monoclonal antibody against hepatocellular carcinoma. Thammasat Int J Sc Tech 2009, 14(1):95-104.
• [26]Manochan S, Puthong S, Gamnarai P, Roytrakul S, Kittisenachai S, Kangsadalampai S, Rojpibulstit P: Hep 88 mAB induced ultrastructural alteration through apoptosis like program cell death in hepatocellular carcinoma. J Med Assoc Thai 2011, 94(Suppl 7):S109-S116.
• [27]Sperandio S, de Belle I, Bredesen DE: An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci U S A 2000, 97(26):14376-14381.
• [28]Wyllie AH, Golstein P: More than one way to go. Proc Natl Acad Sci U S A 2001, 98(1):11-13.
• [29]Raharjo TJ, Widjaja I, Roytrakul S, Verpoorte R: Comparative proteomics of Cannabis sativa plant tissues. J Biomol Tech 2004, 15(2):97-106.
• [30]Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979, 76(9):4350-4354.
• [31]Burnette WN: "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate–polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 1981, 112(2):195-203.
• [32]Harris M: Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004, 5(5):292-302.
• [33]Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, Zhao R, Puravs E, Tra J, Michael CW, Misek DE, Hanash SM: Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 2003, 278(9):7607-7616.
• [34]Ran Q, Wadhwa R, Kawai R, Kaul SC, Sifers RN, Bick RJ, Smith JR, Pereira-Smith OM: Extramitochondrial localization of mortalin/mthsp70/PBP74/GRP75. Biochem Biophys Res Commun 2000, 275(1):174-179.
• [35]Wadhwa R, Taira K, Kaul SC: An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where? Cell Stress Chaperones 2002, 7(3):309-316.
• [36]Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, Lau GK, Beretta L, Fan ST: Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics 2008, 7(2):315-325.
• [37]Chen X, Xu B, Li H, Yang L, Zuo J, Liu W, Liu C: Expression of mortalin detected in human liver cancer by tissue microarrays. Anat Rec (Hoboken) 2011, 294(8):1344-1351.
• [38]Lu WJ, Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R, Luk JM: Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ 2011, 18(6):1046-1056.
• [39]Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R, Luk JM: Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin. Int J Canc 2011, 129(8):1806-1814.
• [40]Wadhwa R, Takano S, Taira K, Kaul SC: Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells. J Gene Med 2004, 6(4):439-444.
• [41]Wadhwa R, Ando H, Kawasaki H, Taira K, Kaul SC: Targeting mortalin using conventional and RNA-helicase-coupled hammerhead ribozymes. EMBO Rep 2003, 4(6):595-601.
• [42]Deocaris CC, Widodo N, Shrestha BG, Kaur K, Ohtaka M, Yamasaki K, Kaul SC, Wadhwa R: Mortalin sensitizes human cancer cells to MKT-077-induced senescence. Cancer Lett 2007, 252(2):259-269.
• [43]Lee AS: GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 2007, 67(8):3496-3499.
• [44]Wygrecka M, Marsh LM, Morty RE, Henneke I, Guenther A, Lohmeyer J, Markart P, Preissner KT: Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood 2009, 113(22):5588-5598.
• [45]Redlitz A, Fowler BJ, Plow EF, Miles LA: The role of an enolase-related molecule in plasminogen binding to cells. Eur J Biochem 1995, 227(1–2):407-415.
• [46]Liu K-J, Shih N-Y: The role of enolase in tissue invasion and metastasis of pathogens and tumor cells. J Cancer Mol 2007, 3(2):45-48.
• [47]Hamaguchi T, Iizuka N, Tsunedomi R, Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima M, Tamesa T, Oka M: Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol 2008, 33(4):725-731.
• [48]Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Fujimoto M, Nishisaka T, Okita K, Oka M, Nakamura K: Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 2005, 5(6):1686-1692.
• [49]Capello M, Ferri-Borgogno S, Cappello P, Novelli F: alpha-Enolase: a promising therapeutic and diagnostic tumor target. FEBS J 2011, 278(7):1064-1074.
• [50]Blanc JF, Lalanne C, Plomion C, Schmitter JM, Bathany K, Gion JM, Bioulac-Sage P, Balabaud C, Bonneu M, Rosenbaum J: Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics 2005, 5(14):3778-3789.
• [51]Ellis RJ: Molecular chaperones: assisting assembly in addition to folding. Trends Biochem Sci 2006, 31(7):395-401.
• [52]Wadhwa R, Yaguchi T, Hasan MK, Taira K, Kaul SC: Mortalin-MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation. Biochem Biophys Res Commun 2003, 302(4):735-742.
• [53]Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR, Mitsui Y, Kaul SC: Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem 1998, 273(45):29586-29591.
• [54]Wadhwa R, Taira K, Kaul SC: Can mortalin be a candidate target for cancer therapy. Cancer Ther 2003, 1:173-178.
• [55]Terman A, Gustafasson B, Brunk UT: Autophagy, organelles and ageing. J Pathol 2007, 211(2):134-143.
• [56]Motyl T, Gajkowska B, Zarzyńska J, Gajewska M, Lamparska-Przybysz M: Apoptosis and autophagy in mammary gland remodeling and breast cancer chemotherapy. J Physiol Pharmacol 2006, 57(Suppl 7):17-32.
• [57]Li N, Zheng Y, Chen W, Wang C, Liu X, He W, Xu H, Cao X: Adaptor protein LAPF recruits phosphorylated p53 to lysosomes and triggers lysosomal destabilization in apoptosis. Cancer research 2007, 67(23):11176-11185.
• [58]Yuan XM, Li W, Dalen H, Lotem J, Kama R, Sachs L, Brunk UT: Lysosomal destabilization in p53-induced apoptosis. Proc Natl Acad Sci Unit States Am 2002, 99(9):6286-6291.
• [59]Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. science 2009, 324(5930):1029-1033.
• [60]Piotrowska U, Adler G, Gardas A, Gietka-Czernel M, Kaniewski M, Banga JP: Cross-reactivity of a monoclonal antibody to the amino terminal region of thyrotropin receptor with the serum protein alpha1-antitrypsin. Thyroid 2002, 12(7):563-570.